Variation in the<i>CYP2D6</i>genotype is not associated with carvedilol dose changes in patients with heart failure

Abstract

Genotype group affiliation and number of adverse drug reactions were not predictive of carvedilol dose during therapy for patients with HF. The Israeli CYP2D6 phenotype distribution in HF patients was consistent with the frequency in the general European population.